Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
FiercePharma1d
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
FiercePharma2d
With efficacy assured, Merck halts another trial of blockbuster-to-be Winrevair
Two months later, Merck and the Winrevair program’s steering committee have agreed to take that action with the HYPERION trial. The roughly 300 participants in HYPERION will be offered access to ...
Investing3d
Merck's SWOT analysis: pharma giant's stock faces China setback, PAH potential
Merck operates in a highly competitive pharmaceutical landscape, particularly in oncology and PAH treatments. In the PAH space, the company faces competition from drugs such as Keros Therapeutics ...
STAT1d
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
Yahoo Finance2d
Merck & Co., Inc. (MRK)
Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: "There's been a lot of ...
The New York Times4d
Kennedy Is Keeping His Stake in Vaccine Litigation
Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...
Morningstar5d
Merck & Co Inc MRK
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
pharmaphorum1d
Pharma must rebuild reputation - Merck and Co's CEO
Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...
Contract Pharma6d
Merck’s WELIREG Accepted for Priority Review by FDA for Pheochromocytoma and Paraganglioma
A supplemental new drug application (sNDA) seeking approval of WELIREG (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and pediatric patients ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
pharmaphorum5d
Merck turns to cardiovascular pipeline for its post-Keytruda future
a TGF-beta-targeting PAH drug Merck acquired via its $11.5 billion takeover of Acceleron Pharma last year. Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck ...